Summit Therapeutics to Present Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022
13 oct. 2022 08h00 HE
|
Summit Therapeutics Inc.
Menlo Park, California, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) and its product candidate, ridinilazole, will have an oral podium...
The Biocodex Microbiota Foundation calls for Canadian proposals to study the microbiome’s role in health and diseases
04 août 2022 10h26 HE
|
Biocodex Canada
The Biocodex Microbiota Foundation is looking for academics and scientists in Canada to apply for a €25,000 research grant aimed at helping advance the study of the gut microbiome MONTREAL, Aug. 04,...
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2022
11 mai 2022 16h30 HE
|
Summit Therapeutics Inc.
Cambridge, MA, May 11, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on operational...
Taconic Biosciences and Biomodels Establish Microbiome Initiative
26 avr. 2022 09h00 HE
|
Taconic Biosciences
RENSSELAER, N.Y., April 26, 2022 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, and Biomodels, a provider of contract research services...
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2021
17 mars 2022 16h14 HE
|
Summit Therapeutics Inc.
Cambridge, MA, March 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its...
Summit Therapeutics Today Presents Its Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference
10 janv. 2022 08h00 HE
|
Summit Therapeutics Inc.
Cambridge, Massachusetts, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) reminds interested stakeholders that it will today present the...
Summit Therapeutics to Present Company Vision at 40th Annual J.P. Morgan Healthcare Virtual Conference
05 janv. 2022 07h30 HE
|
Summit Therapeutics Inc.
Cambridge, Massachusetts, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced that it will present the Company’s vision...
Summit Therapeutics Announces Topline Results for Phase III Ri-CoDIFy Study for C. Difficile Infection
20 déc. 2021 08h30 HE
|
Summit Therapeutics Inc.
Cambridge, MA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit” or the “Company”) today announced topline results for the Phase III Ri-CoDIFy study evaluating its...
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2021
15 nov. 2021 08h30 HE
|
Summit Therapeutics Inc.
Cambridge, Massachusetts, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on...
The Biocodex Microbiota Foundation calls for Canadian proposals to study the microbiome’s role in health and diseases
28 juil. 2021 10h39 HE
|
Biocodex Canada
MONTREAL, July 28, 2021 (GLOBE NEWSWIRE) -- The Biocodex Microbiota Foundation, an organization founded by Biocodex and dedicated to inspiring scientific projects that explore the microbiome, is...